Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 51, Issue 1, 2010, Pages 95-106

  Del Poeta, Giovanni ^a   Del Principe, Maria Ilaria ^a   Maurillo, Luca ^a   Rossi, Francesca Maria ^b   Buccisano, Francesco ^a   Ammatuna, Emanuele ^a   Simotti, Cristina ^a   Zucchetto, Antonella ^b   Catalano, Gianfranco ^a   Bulian, Pietro ^b   Bruno, Antonio ^a   Venditti, Adriano ^a   De Fabritiis, Paolo ^a   Gattei, Valter ^b   Amadori, Sergio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Bcl 2; CD71; CLL; Flow cytometry; Prognostic factors; ZAP 70

Indexed keywords

BETA 2 MICROGLOBULIN; CD71 ANTIGEN; FLUDARABINE PHOSPHATE; PROTEIN BCL 2; PROTEIN KINASE ZAP 70;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; APOPTOSIS; CELL PROLIFERATION; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, TRANSFERRIN; TREATMENT OUTCOME; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 74949088506     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903350421     Document Type: Article

References (48)

1. Faderl S, Keating MJ, Do KA, et al. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 2002;16:1045-1052. (Pubitemid 34618843)
2. Goolsby C, Paniagua M, Tallman M, Gartenhaus RB. Bcl-2 regulatory pathway is functional in chronic lymphocytic leukemia. Cytometry B Clin Cytom 2005;63:36-46.
3. Jaroslav P, Martina H, Jiri S, et al. Expression of cyclin D1, D2 and D3 and Ki-67 in leukemia. Leuk Lymphoma 2005; 46:1605-1612.
4. Obermann EC, Went P, Tzankov A, et al. Cell cycle phase distribution analysis in chronic lymphocytic leukaemia: a significant number of cells reside in early G1-phase. J Clin Pathol 2006;60:794-797.
5. Trowbridge IS, Omary MB. Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin. Proc Natl Acad Sci USA 1981;78:3039-3043.
6. Omary MB, Trowbridge IS, Minowada J. Human cell-surface glycoprotein with unusual properties. Nature 1980;286:888-891.
7. Habeshaw JA, Lister TA, Stansfeld AG, Greaves MF. Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. Lancet 1983; 1:498-501.
8. Pileri S, Gobbi M, Rivano MT, Martinelli G. Immunohistological study of transferrin receptor expression in non-Hodgkin's lymphoma. Br J Haematol 1984;58:501-508.
9. Medeiros LJ, Picker LJ, Horning SJ, Warnke RA. Transferrin receptor expression by non-Hodgkin's lymphomas: correlation with morphologic grade and survival. Cancer 1988;61:1844-1851.
10. Marschitz I, Tinhofer I, Hittmair A, Egle A, Kos M, Greil R. Analysis of bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitative techniques. Am J Clin Pathol 2000;113:219-229.
11. Pepper C, Hoy T, Bentley P. Elevated bcl-2/bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated with in vivo chemoresistance. Leuk Lymphoma 1998;28:355-361.
12. Wu JM, Borowitz MJ, Weir EG. The usefulness of CD71 expression by flow cytometry for differentiating indolent from aggressive CD10+ B-cell lymphomas. Am J Clin Pathol 2006; 126:39-46.
13. Metzgeroth G, Schultheis B, Kuhn C, et al. The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia. Clin Chem Lab Med 2007;45:1313-1318.
14. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847.
15. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854.
16. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin variable region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-1775.
17. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893-901.
18. Del Principe MI, Del Poeta G, Buccisano F, et al. Clinical significance of ZAP-70 expression in B-cell chronic lymphocytic leukemia. Blood 2006;108:853-861.
19. Decker T, Hipp S, Ringshausen I, et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 2003;101:278-285.
20. Decker T, Sandherr M, Goetze K, Oelsner M, Ringshausen I, Peschel C. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Ann Hematol 2009;88:221-227.
21. Jantus-Lewintre E, Sarsotti E, Terol MJ, Benet I, Garcia-Conde J. Bortezomib induces different apoptotic rates in BCLL cells according to IgVH and BCL-6 mutations. Clin Transl Oncol 2006;8:805-811.
22. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-684.
23. O'Brien S, Moore JO, Boyd TE, et al. Randomized phase III trial of fludrabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007;25:1114-1120.
24. Veldurthy A, Patz M, Hagist S, et al. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood 2008;112:1443-1452.
25. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-5456.
26. Del Poeta G, Maurillo L, Venditti A, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001;98:2633-2639.
27. Gattei V, Bulian P, Del Principe MI, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 2008;111:865-873.
28. Del Principe MI, Del Poeta G, Venditti A, et al. Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia. Haematologica 2004;89:1468-1475.
29. Gattei V, Degan M, Gloghini A, et al. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 1997;89:2048-2059.
30. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998;102:1515-1525.
31. Degan M, Bomben R, Bo MD, et al. Analysis of IgV gene mutation in B cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery. Br J Haematol 2004;126:29-42.
32. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute Sponsored Working Group Guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;29:4990-4997.
33. Chiorazzi N. Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. Best Pract Res Clin Haematol 2007;20:399-413.
34. Packham G, Stevenson FK. Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology 2005;114:441-449.
35. Pepper C, Lin TT, Pratt G, et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 2008;112:3807-3817.
36. Damle RN, Batliwalla FM, Ghiotto F, et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood 2004;103:375-382.
37. Ricca I, Rocci A, Drandi D, et al. Telomere length identifies two different prognostic subgroups among VH-unmutated Bcell chronic lymphocytic leukemia patients. Leukemia 2007; 21:697-705.
38. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005;115.755-764.
39. Judd W, Poodry CA, Strominger JL. Novel surface antigen expressed on dividing cells but absent from non dividing cells. J Exp Med 1980;152:1430-1435.
40. Damle RN, Ghiotto F, Valetto A, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002;99:4087-4093.
41. Horii A, Yoshida J, Hattori K, et al. DNA ploidy, proliferative activities, and immunophenotype of malignant lymphoma: application of flow cytometry. Head Neck 1998; 20:392-398.
42. Braylan RC. Flow cytometric DNA analysis in the diagnosis and prognosis of lymphoma. Am J Clin Pathol 1993;99:374-380.
43. Damle RN, Temburni S, Calissano C, et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 2007;110:3352-3359.
44. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002;100:4609-4614.
45. Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008;111:846-855.
46. Bogner C, Sandherr M, Perker M, et al. Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells. Ann Hematol 2006;85: 458-462.
47. Saka B, Atkan M, Sami U, Oner D, Sanem O, Dincol G. Prognostic importance of soluble CD23 in B-cell chronic lymphocytic leukemia. Clin Lab Haematol 2006;28: 30-35.
48. Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukaemia. Blood 2008;112:1923-1930.